– Composition of matter patent strengthens proprietary position of CYB004 as a deuterated DMT compound until 2041- TORONTO–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, today announced that the U.S. Patent and Trademark Office (“USPTO”) has granted U.S. patent 11,242…


Previous articleMYND Diagnostics Inc. Announces Participation in Approved Monash University (Australia) Government Funded $3 Million Clinical Trial
Next articlePsyence Group Announces DTC Eligibility Approval in the U.S.